 |
 |
 |
 |
 |
|
 |
 |
 |
 |
Absorption
Absorption Systems uses a variety of in situ, in vitro, and in vivo models to classify the absorption potential of our customers' compounds. These are the models on which our company was founded more than ten years ago. Our tag line, "The Drug Absorption Company", is no idle boast... it captures what we are best known for and what we know better than anyone else.
Our Chief Scientist, Ismael Hidalgo, pioneered the use of Caco-2 cell monolayers to predict intestinal drug absorption twenty years ago. His seminal paper on the topic (Hidalgo et al. Gastroenterology 1989; 96:736-749) has been cited more than 1000 times. We are comfortable saying that nobody knows the Caco-2 model better than we do. We work with it every day.
We routinely run assays for our customers that determine:
- active and passive transport of a compound across cell monolayers,
- active and passive transport of a compound across skin, buccal, or nasal tissue,
- active and passive transport of a compound across intestinal segments,
- the pharmacokinetics of a compound in mice, rats, mini-pigs, dogs, and non-human primates.
A description of our various absorption-related assays can be found in the Assay Data Sheets listed in the Related Literature section below. Click on the ones you want to download.
|
Please contact Absorption Systems if you would like our help in determining the absorption properties of your compounds.
Related Literature
This assay is used to determine the chemical stability of a test compound in buffer.
Click Here to Download
This assay is used to determine the permeability of a test compound through Caco-2 cell monolayers in the apical-to-basolateral direction.
Click Here to Download
This assay is used to determine the permeability of a test compound through Caco-2 cell monolayers in the apical-to-basolateral and basolateral- to-apical direction.
Click Here to Download
This assay is used to determine the unidirectional permeability of a test compound through intestinal tissue segments (duodenum, ileum, jejunum and colon).
Click Here to Download
This assay is used to determine the bidirectional permeability of a test compound through intestinal tissue segments (duodenum, ileum, jejunum and colon).
Click Here to Download
This assay is used to determine the unidirectional permeability of a test compound through freshly excised porcine buccal epithelium.
Click Here to Download
This assay is used to determine the unidirectional permeability of a test compound through freshly excised porcine nasal epithelium.
Click Here to Download
This assay is used to determine the unidirectional permeability of a test compound through excised skin from humans or pigs.
Click Here to Download
This assay is used to determine the permeability of a test compound through Caco-2 cell monolayers in the apical-to-basolateral direction.
Click Here to Download
This assay is used to determine the permeability of a test compound through Caco-2 cell monolayers in both the apical-to-basolateral and basolateral-to-apical direction.
Click Here to Download
This assay is used to assess the potential of a test compound to induce P-glycoprotein (P-gp) in a human intestinal cell line.
Click Here to Download
This screening assay is used to determine the bioavailability of test compounds relative to a reference compound after oral administration to rats.
Click Here to Download
This assay uses in situ brain perfusion to determine both the potential brain penetration of test compound and whether it is a P-gp substrate.
Click Here to Download
This assay is used to determine the absolute bioavailability of a test compound in mice.
Click Here to Download
This assay is used to determine the bioavailability of a test compound in dogs when the compound is administered by at least two different routes.
Click Here to Download
This screening assay is used to determine the bioavailability / exposure of test compounds after two routes of administration to male mice.
Click Here to Download
This screening assay is used to determine the bioavailability / exposure of test compounds after two routes of administration to male rats.
Click Here to Download
This assay is used to determine the bioavailability / exposure of test compounds in male dogs after two routes of administration.
Click Here to Download
This assay is used to determine the bioavailability / exposure of a test compound in dogs after two routes of administration (non-crossover).
Click Here to Download
This screening assay uses the general CYP inhibitor, 1-aminobenzotriazole (ABT), to determine the role of absorption vs. first-pass metabolism in limiting the systemic exposure of a test compound in rats.
Click Here to Download
This non-GLP assay is used to determine a preliminary BCS permeability classification by measuring the permeability of a test compound through Caco-2 cell monolayers in both the apical-to-basolateral and basolateral-to-apical direction.
Click Here to Download
This GLP assay is used to determine the BCS permeability classification of a test compound across Caco-2 cell monolayers at three concentrations and two pH values.
Click Here to Download
Brochures
A quick and cost-effective way to distinguish between poor absorption and rapid first-pass metabolism for compounds with poor oral bioavailability
Click Here to Download
Testing for permeability across rabbit cornea and conjunctiva in vitro
Click Here to Download